Perigon Wealth Management LLC Purchases 4,543 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Perigon Wealth Management LLC lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 31.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,820 shares of the company's stock after acquiring an additional 4,543 shares during the period. Perigon Wealth Management LLC owned approximately 0.06% of TransMedics Group worth $1,266,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NBC Securities Inc. bought a new stake in shares of TransMedics Group during the 1st quarter worth approximately $25,000. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group during the 4th quarter worth approximately $31,000. AlphaQuest LLC acquired a new position in TransMedics Group during the 4th quarter worth approximately $52,000. Rakuten Securities Inc. increased its position in TransMedics Group by 68.3% during the 4th quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock worth $84,000 after purchasing an additional 550 shares in the last quarter. Finally, Sava Infond d.o.o. acquired a new position in TransMedics Group during the 4th quarter worth approximately $94,000. Institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Oppenheimer upped their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $127.33.

Insider Activity

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider now directly owns 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 6,000 shares of the stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by insiders.

TransMedics Group Trading Up 1.1%

NASDAQ:TMDX opened at $131.45 on Friday. The firm's fifty day moving average is $118.51 and its 200-day moving average is $86.28. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The firm has a market cap of $4.45 billion, a P/E ratio of 96.65 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period in the prior year, the firm posted $0.35 EPS. The company's quarterly revenue was up 48.2% on a year-over-year basis. Equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.